Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR By Ogkologos - July 28, 2025 793 0 Facebook Twitter Google+ Pinterest WhatsApp Final results from the IMpassion031 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Alzheimer’s-Linked Protein May Help Melanoma Spread to Brain April 1, 2022 Lorlatinib Slows Growth of ALK-Positive Lung Cancers, May Prevent Brain Metastases July 10, 2024 Your NCI: Top Priorities from AACR 2026 May 4, 2026 A Diagnosis of Advanced Lung Cancer Is Not a Death Sentence November 19, 2020 Load more HOT NEWS Fourth Vaccine Dose Increases in Humoral Immunity Against Omicron Variants in... Man Spent 20 Years Tracking Down And Buying His Late Mother’s... Can Fertility Drugs or IVF Increase My Risk for Cancer? The Potential of AI to Improve Cancer Care is Only Going...
